BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 - an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease

Stock Information for MedAvail Holding

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About MedAvail Holding

BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease
BioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
BioRestorative Awarded Notice of Allowance for Japanese Patent - Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market
BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio
BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit
BioRestorative CEO Lance Alstodt Interviewed on "The Big Biz Show"
BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.